• United States
  • Canada
  • Mexico
  • China
  • Middle East
  • Japan
  • Europe
  • Sales
  • Marketing
emphycorp logo
emphycorp logo
  • About Us
    • About Us
    • Management and Advisors
    • OUR MEDICAL STUDIES
  • Our Drug Pipeline
    • Our Drug Pipeline
    • PULMONARY FIBROSIS TREATMENT®
    • COVID-19 TREATMENT®
    • COVID-19 LONG HAULERS TREATMENT®
    • FLU TREATMENT®
    • UNMET NEEDS BREATHING TREATMENT®
    • NON-STEROIDAL COPD NASAL SPRAY®
    • 70% LOWER STEROID COPD®
    • NON-STEROIDAL ALZHEIMER’S NASAL SPRAY®
    • CONCUSSIONS TREATMENT®
    • DRUG FREE CANCER PRE-TREATMENT®
    • SMOKING CESSATION ORAL SPRAY®
  • Conditions We Can Treat
    • HYPOXEMIA
    • PULMONARY FIBROSIS
    • COVID-19
    • COVID LONG HAULERS
    • FLU
    • ASTHMA
    • COPD
    • EMPHYSEMA
    • SARCOIDOSIS
    • CYSTIC FIBROSIS (CF)
    • CHRONIC BRONCHITIS
    • INTERSTITIAL LUNG DISEASE
    • VIRAL and BACTERIAL Infections
  • FDA Submissions
    • REGULATION OF NITRIC OXIDE
    • SODIUM PYRUVATE
    • N115 FDA SUBMISSIONS
  • Contact Us
    • Investor Relations
    • Partnerships
  • News/Press/Blog
    • Emphycorp News & Peer Reviewed Articles
    • PRESS RELEASES
    • Blog
    • NEW PULMONARY FIBROSIS TREATMENT
  • United States
  • Canada
  • Mexico
  • China
  • Middle East
  • Japan
  • Europe
  • Sales
  • Marketing
Blog
  1. Home
  2. Blog
  • Show all
  • Uncategorized
  • Medical News
cision-logo

November 7, 2021

EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis

by Emphycorp

emphycorp logo white

Terms and Conditions

Focus Pages

  • About Emphycorp
 
  • Emphycorp News
 
  • Investor Relations

Address

84 Park Avenue, Suite E-102
Flemington, New Jersey
08822 USA

Start a conversation

SALES: (973) 586-4421
MARKETING: (973) 586-4421

© 2024 Emphycorp Inc. . All rights reserved

Privacy Preference Center

Privacy Preferences